Actavis Enters U.S. Generic Market Through $500 Mil. Amide Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Iceland-based Actavis will diversify its European-centric revenue base through the acquisition of Amide, located in New Jersey. An Amide manufacturing site currently under construction and slated for completion in 2006 could significantly boost U.S. capacity for the combined companies.
You may also be interested in...
Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Boothe talks with “The Pink Sheet” DAILY about Actavis’ global and U.S. strategies as the top five generics company looks to keep growing.
Actavis Executive VP-U.S. Commercial And Administration Doug Boothe: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Boothe talks with “The Pink Sheet” DAILY about Actavis’ global and U.S. strategies as the top five generics company looks to keep growing.
Actavis' U.S. Portfolio To Get A Boost From Alpharma Generic Acquisition
The Iceland-based firm will become a top-five global generic player after acquiring Alpharma's generic business for $810 mil.